secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001213900-26-052231
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio secures long-term umbilical cord supply for CORDStrom MSC platform via Anthony Nolan agreement
--------------------------------------------------------------------------------

- AN granted exclusive license to use donor materials; INmune Bio added as party with joint liability for royalty payments.
- AN receives 2% royalty on net sales of each product, capped at £5M annually; £400+VAT fees per cord tissue, CPI-adjusted annually.
- Term runs until 10 years after first commercial sale; either party may terminate with 30 days (IMB/INMB) or 6 months (AN) notice.
- Pipeline targets RDEB, CORDStrom-col7a, CORDStrom-TRAIL (oncology), osteoarthritis, and systemic lupus erythematosus (SLE).
- Materials handled per GMP and HTA standards; enables global regulatory compliance (FDA, EMA, MHRA).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390026052231/0001213900-26-052231-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390026052231/ea0288685-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-052231

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer